Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. May 14, 2014; 20(18): 5320-5330
Published online May 14, 2014. doi: 10.3748/wjg.v20.i18.5320
Published online May 14, 2014. doi: 10.3748/wjg.v20.i18.5320
Liver transplantation for nonalcoholic fatty liver disease: New challenges and new opportunities
Mina Shaker, Adam Tabbaa, Mazen Albeldawi, Naim Alkhouri, Department of Gastroenterology and Hepatology, Digestive Disease Institute, Cleveland Clinic, OH 44195, United States
Author contributions: All the authors performed literature research, wrote the paper; Shaker M designed the figure.
Correspondence to: Naim Alkhouri, MD, Department of Gastroenterology and Hepatology, Digestive Disease Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, United States. alkhoun@ccf.org
Telephone: +1-216-4457126 Fax: +1-216-4442974
Received: September 28, 2013
Revised: January 10, 2014
Accepted: January 19, 2014
Published online: May 14, 2014
Revised: January 10, 2014
Accepted: January 19, 2014
Published online: May 14, 2014
Core Tip
Core tip: Nonalcoholic fatty liver disease (NAFLD) is projected to become the most common indication for liver transplantation in the United States by 2030 with high risk for disease recurrence after transplantation. De novo NAFLD may develop in patients transplanted for other indications due to the high prevalence of obesity and metabolic syndrome. The optimal management of NAFLD after liver transplantation requires future studies.